Mozambique Pharmaceuticals & Healthcare Report

Published 05 August 2015

  • 55 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Mozambique Pharmaceuticals & Healthcare Report

BMI View: The Mozambican government's efforts to achieve universal health coverage through its 2014-2019 Health Sector Strategic Plan along with the country ' s robust economic performance and growing chronic disease burden will be the pharmaceutical and healthcare sector ' s main driving factor for growth. However, opportunities for multinational drugmakers will continue to be heavily outweighed by the high risks associated with the country such as weak intellectual property protection, poor regulatory environment and political instability.

Headline Expenditure Forecasts

  • Pharmaceuticals: MZN7.59bn (USD242mn) in 2014 to MZN8.28bn (USD227mn) in 2015; +9.0% in local currency and -6.3% in US dollar terms. Forecast revised downwards from last quarter.

  • Healthcare: MZN34.99bn (USD1.12bn) in 2014 to MZN38.89bn (USD1.07bn) in 2015; +11.1% in local currency and -4.5% in US dollar terms. Forecast revised upwards from last quarter.

Risk/Reward Index

Mozambique has a score of 29.5 out of 100 - just lower than Uganda (30.7) - in our Pharmaceutical Risk/Reward Index (RRI) for Q415, marking no change from last quarter's score. The country is ranked 26th most attractive pharmaceutical market in the Middle East and Africa (MEA) region.

Key Trends And Developments

June 2015

The Mozambican government is working to ensure that essential drugs reach all healthcare units in the country, according to Health Minister Nazira Abdula. To date, 18,794 kits of essential drugs have been distributed in 2015 for lower level health units, as well as 26,928 kits for community health workers, to cover needs until October 2015. The government has approved a Strategic Plan for Pharmaceutical Logistics in a bid to ensure a regular and continuous supply of all essential drugs and equipment. The plan seeks to guarantee timely delivery, minimise stocks and reduce distribution costs by obtaining accurate data from the points of consumption.

The Japanese government, through the Japan...

BMI Industry View
7
SWOT
9
Political
10
Economic
11
Operational Risk
12
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Mozambique 2011-2019)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2011-2019)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2011-2019)
19
Key Risks To BMI's Forecast Scenario
19
Macroeconomic Forecasts
21
Economic Analysis
21
Table: Economic Activity (Mozambique 2010-2019)
24
Industry Risk Reward Ratings
25
Middle East and Africa Risk/Reward Index - Q4 2015
25
Mozambique Risk/Reward Index
32
Rewards
32
Risks
32
Market Overview
33
Industry Trends And Developments
34
Epidemiology
34
Clinical Trials
36
Regulatory Development
37
Regulatory Development
37
Intellectual Property Issues
38
Pricing Regime
38
Competitive Landscape
39
Domestic Industry
39
Company Developments
39
Company Profile
41
Sociedade Mo-ambicana de Medicamentos (SMM)
41
Demographic Forecast
43
Table: Population Headline Indicators (Mozambique 1990-2025)
44
Table: Key Population Ratios (Mozambique 1990-2025)
44
Table: Urban/Rural Population & Life Expectancy (Mozambique 1990-2025)
45
Table: Population By Age Group (Mozambique 1990-2025)
45
Table: Population By Age Group % (Mozambique 1990-2025)
46
Glossary
48
Methodology
50
Pharmaceutical Expenditure Forecast Model
50
Healthcare Expenditure Forecast Model
50
Notes On Methodology
51
Risk/Reward Index Methodology
52
Index Overview
53
Table: Pharmaceutical Risk/Reward Index Indicators
53
Indicator Weightings
54

The Mozambique Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Mozambique Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Mozambique pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Mozambique, to test other views - a key input for successful budgeting and strategic business planning in the Mozambican pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Mozambican pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Mozambique.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%